Aaron T. Wild, MD

Find Dr. Wild’s full list of publications on PubMed here.

• Wild AT, Yamada Y. Treatment options in oligometastatic disease: stereotactic body radiation therapy— focus on colorectal cancer. Visc Med. 2017; 33(1):54-61. PMID: 28612018.
• Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):571-9. PMID: 26867885.
• Wild AT, Dholakia AS, Fan KY, Kumar R, Moningi S, Rosati LM, Laheru DA, Zheng L, De Jesus-Acosta A, Ellsworth SG, Hacker-Prietz A, Voong KR, Tran PT, Hruban RH, Pawlik TM, Wolfgang CL, Herman JM. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Gastrointest Oncol. 2015;6(2):115-25. PMID: 25830031.
• Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. Reirradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: Experience from two institutions. J Gastrointest Oncol. 2013;4(4):343-51. PMID: 24294505.
• Wild AT, Gandhi N, Chettiar ST, Aziz KA, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA, Velarde E, Menon S, Geschwind JF, Cosgrove D, Pawlik TM, Maitra A, Wong J, Hales RK, Torbenson MS, Herman JM, Tran PT. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PLoS ONE. 2013;8(6):e65726. PMID: 23762417.
• Wild AT, Ye X, Ellsworth S, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015;38(3):259-65. PMID: 23648440.
• Wild AT, Fan KY, Herman JM. Management of pancreatic cancer. Curr Probl Cancer. 2013;37(5):259-61. PMID: 24331179.
• Kumar R, Wild AT [co-first author], Ziegler MA, Smith K, Kang J, Hooker TK, Dah SD, Tran PT, Zeng J, Pawlik TM, Tryggestad E, Ford E, Herman JM. Stereotactic body radiation therapy planning with duodenal sparing using volumetric modulated arc therapy versus intensity modulated radiation therapy for locally advanced pancreatic cancer: A dosimetric analysis. Med Dosim. 2013;38(3):243-50. PMID: 23540490.
• Herman JM, Wild AT [co-first author], Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. A randomized phase III multi-institutional study of TNFerade™ biologic with 5-fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results. J Clin Oncol. 2013;31(7):886-94. PMID: 23341531.
• Gandhi N, Wild AT [co-first author], Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT. Novel Hsp90 inhibitor NVP-AUY022 radiosensitizes prostate cancer cells. Cancer Biol Ther. 2013; 14(4): 347-56. PMID: 23358469.
• Smith JA, Wild AT [co-first author], Singhi A, Raman SP, Qiu H, Kumar R, Hacker-Prietz A, Hruban RH, Kamel IR, Efron J, Wick EC, Azad NS, Diaz LA, Le Y, Armour EP, Gearhart SL, Herman JM. Clinicopathologic comparison of high-dose-rate endorectal brachytherapy versus conventional chemoradiotherapy in the neoadjuvant setting for resectable stage II and III low rectal cancer. Int J Surg Oncol. 2012; 406568. PMID: 22830003.
• Wild AT, Sponseller PD, Stec AA, Gearhart JP. The role of osteotomy in surgical repair of bladder exstrophy. Semin Pediatr Surg. 2011;20(2):71-78. PMID: 21453849.
• Fan KY, Wild AT, Halappa VG, Kumar R, Ellsworth S, Ziegler M, Garg T, Rosati LM, Su Z, Hacker-Prietz A, Pawlik TM, Cosgrove DP, Hong KK, Kamel IR, Geschwind JF, Herman JM. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials. 2016 Sep;50:143-9. PMID: 27520932
• Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, Brock M, Balmanoukian A, Ye X. Survival following treatment with radiation and chemotherapy in patients with solid tumors and severe treatment-related lymphopenia. J Natl Compr Canc Netw. 2015;13(10):1225-31. PMID: 26483062.
• Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O’Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: Implications for surgical management. Ann Surg. Ann Surg. 2016;263(1):153-61. PMID: 26020105.
• Elnahal SM, Moningi S, Wild AT, Dholakia AS, Hodgin M, Fan KY, Huang P, Pronovost P, Pawlik TM, Herman JM. Improving safe patient throughput in a multidisciplinary oncology clinic. Physician Leadersh. 2015;2(2):56-60, 62, 64-5. PMID: 26211213.
• Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahu CA, Griffith MB, Pawlik TM, Pai J, O’Reilly E, Fisher G, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128-37. PMID: 25538019.
• Walker AJ, Alcorn SR, Narang AK, Nugent KM, Wild AT, Herman JM, Tran PT. Radiosensitizers in pancreatic cancer—preclinical and clinical exploits with molecularly targeted agents. Curr Probl Cancer. 2013;37(5):301-12. PMID: 24331186.
• Fan KY, Dholakia AS, Wild AT, Su Z, Hacker-Prietz A, Kumar R, Hodgin M, Hsu CC, Le DT, De JesusAcosta A, Diaz Jr LA, Laheru DA, Hruban RH, Fishman EK, Brown TD, Pawlik TM, Wolfgang CL, Tran PT, Herman JM. Baseline hemoglobin-A1c impacts clinical outcomes in Patients with pancreatic cancer. J Natl Compr Canc Netw. 2014;12(1):50-57. PMID: 24453292.
• Dholakia AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P, Laheru DA, Zheng L, De JesusAcosta A, Le DT, Schulick RD, Edil BH, Yovino SG, Pawlik TM, Iacobuzio-Donahue AC, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM. Successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer is not dependent on improved tumor-vessel relationships. J Radiat Oncol. 2013;2(4):413-425. PMID: 25755849.
• Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy following resection for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2013;87(3):458-9. PMID: 24074918.
• Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, DeWeese TL, Antonarakis ES, Tran PT. Molecularly targeted agents as radiosensitizers in cancer therapy—Focus on prostate cancer. Int J Mol Sci. 2013;14(7):14800-32. PMID: 23863691.
• Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung C, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT. The Twist box is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res. 2013;11(11):1387-400. PMID: 23982216.
• Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Phase 2 Study of Erlotinib Combined with Adjuvant Chemoradiation and Chemotherapy in Patients with Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2013;86(4):678-85. PMID: 23773391.
• Jabbour SK, Patel S, Herman JM, Wild A, Nagda SN, Altoos T, Tunceroglu A, Azad, N, Gearheart S, Moss RA, Poplin E, Levinson LL, Chandra RA, Moore DF, Chen C, Haffty BG, Tuli R. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol. 2012; 891067. PMID: 22934164.
• Khashab MA, Kim KJ, Tryggestad EJ, Wild AT, Roland T, Ziegler MA, Shin EJ, Sharaiha RZ, Singh VK, Lennon AM, Canto MI, Herman JM. Comparative analysis of traditional and visicoil fiducials implanted during endoscopic ultrasound for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointest Endosc. 2012;76(5):962-71. PMID: 23078921.
• Qiu H, Wild AT, Wang H, Fishman EK, Hruban RH, Laheru DA, Kumar R, Hacker-Prietz A, Tuli R, Tryggestad E, Schulick RD, Cameron JL, Edil BH, Pawlik TM, Wolfgang CL, Herman JM. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: Implications for radiation therapy planning. Radiother Oncol. 2012;104(2):167-72. PMID: 22883106.
• Begly JP, Wild AT, Garzon-Muvdi J, Carrino JA, McFarland EG. Sports Health orthopaedic magnetic resonance imaging challenge: shoulder pain from a fall while surfing. Sports Health. 2012;4(3):261-3. PMID: 23016097.
• Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song D, Deweese TL. Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med. 2012;12(6):772-87. PMID: 22292443

• Wild AT, Wang Y, Wu W, Haddock SL, Chan TA. Exploitation of 2-hydroxyglutarate-mediated deficiency in homologous recombination with PARP inhibition to achieve radiosensitization in IDH-mutant tumors. Oral presentation at the 2018 ASTRO Annual Meeting, San Antonio, TX, October 21-24, 2018.
• Leeman JE, Shepherd A, Wild A, Imber B, Pei X, Gelb E, Travis W, Adusumilli P, Jones D, Isbell J, Chaft J, Wu A, Rimner A. Tumor spread through airspaces and histologic subtype predict outcomes following post-operative radiotherapy for locally advanced lung adenocarcinoma. Oral presentation at the 2017 ASTRO Annual Meeting, San Diego, CA, September 25-27, 2017.
• Wild A, Fan KY, Dholakia AS, Ford E, Kumar R, Ye X, Tran PT, Grossman SA, Herman JM, Ellsworth SG. Stereotactic body radiation therapy results in less severe treatment-related lymphopenia than conventional chemoradiation therapy in patients with locally advanced pancreatic cancer. Oral presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
• Dholakia AS, Kumar R, Raman SP, Yovino SG, Wild AT, Fan KY, Hacker-Prietz A, Tran PT, Wolfgang CL, Herman JM. Mapping Patterns of Local Failure Following Pancreaticoduodenectomy for Pancreatic Cancer: A New Approach to Adjuvant Radiation Fields. Oral presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
• Dholakia AS, Kumar R, Wild AT, Fan KY, Hacker-Prietz A, Ellsworth S, Raman SP, Le DT, Laheru DA, De Jesus-Acosta A, Zheng L, Fishman E, Hruban RH, Weiss MJ, Pawlik TM, Cameron JL, Wolfgang CL, Herman JM. Patterns of local failure following pancreaticoduodenectomy for resectable pancreatic ductal adenocarcinoma. Oral presentation at the 46th Annual Meeting of the Pancreas Club, Orlando, FL, May 17- 18, 2013.
• Dholakia AS, Fan KY, Wild AT, Hacker-Prietz A, Le DT, De Jesus-Acosta A, Diaz LA, Laheru DA, Hruban RH, Fishman EK, Pawlik TM, Wolfgang CL, Herman JM. Hemoglobin-A1c as a predictor of clinical outcomes in patients seen in a pancreas multidisciplinary cancer clinic. Oral presentation at the American Radium Society 95th Annual Meeting, Scottsdale, AZ, April 27-May 1, 2013.
• Fan KY, Wild AT, Hacker-Prietz A, Wood L, Blackford AL, Tran PT, Kumar R, Ellsworth S, Dholakia A, Zheng L, Le DT, De Jesus-Acosta A, Rasheed Z, Makary MA, Weiss MJ, Cameron JL, Pawlik TM, Laheru DA, Hruban RH, Fishman EK, Wolfgang CL, Herman JM. Treating pancreatic cancer patients with erlotinib based adjuvant therapy following pancreaticoduodenectomy or pancreatectomy. Oral presentation at the American Radium Society 95th Annual Meeting, Scottsdale, AZ, April 27-May 1, 2013.
• Kumar R, Ziegler MA, Wild AT, Fan KY, Dholakia AS, Ellsworth S, Pawlik TM, Kamel IR, Herman JM, Geschwind JFH. Efficacy of radioembolization treatments with Yttrium-90 microspheres for liver metastases. Oral presentation at the American Brachytherapy Society 2013 Annual Meeting, New Orleans, LA, April 18-20, 2013.
• Dholakia AS, Hacker-Prietz A, Wild A, Raman S, Laheru D, Zheng L, Le D, Pawlik T, Makary M, Wolfgang C, De Jesus-Acosta A, Herman J. Radiographic changes associated with surgical resection following neoadjuvant radiation therapy for locally advanced pancreatic adenocarcinoma. Oral presentation at the Americas Hepato-Pancreato-Biliary Association (AHPBA) 2013 Annual Meeting, Miami, FL, February 20-24, 2013.
• Wild AT, Chang DT, Goodman KM, Laheru DA, Zheng L, Diaz LA, Le DT, Raman SP, Leal JP, Chaudhry MA, Sugar E, Columbo LA, Tom A, Limaye MR, Edil BH, Oteiza K, Hacker-Prietz A, Wolfgang CL, Koong A, Herman JM. A Phase II Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarcinoma. Oral presentation at ASTRO’s Cancer Imaging and Radiation Therapy Symposium: A Multidisciplinary Approach, Orlando, FL, February 8-9, 2013. PMID: 24674559.
• Ziegler MA, Wild AT, Pawlik TM, Laheru DA, Rajasenan T, Wolfgang CL, Herman JM. Assessment of consistency in treatment recommendations among patients seen at a comprehensive pancreatic cancer multidisciplinary clinic. Oral presentation at the American College of Radiology Driving Value into Your Organization Through Quality and Safety Improvements Conference, Scottsdale, AZ, February 17-18, 2012.
• Wild AT, Begly JP, Garzon-Muvdi J, Desai P, McFarland EG. Chest pain in a female lacrosse player. Oral presentation at the 57th Annual Meeting and Inaugural World Congress on Exercise is Medicine, Baltimore, MD, June 1-5, 2010.